Overview
Congenital disorders of glycosylation (CDG) with epilepsy as a major feature are a group of rare inherited metabolic conditions where the body cannot properly attach sugar molecules (glycans) to proteins and fats. This process, called glycosylation, is essential for many body functions, including brain development and nervous system signaling. When glycosylation goes wrong, it can affect many organs, but in this particular group, seizures (epilepsy) are one of the most prominent and troublesome symptoms. Children with these conditions typically develop seizures early in life, often in infancy or early childhood. The seizures can be difficult to control with standard anti-seizure medications. Other common features may include developmental delay, intellectual disability, low muscle tone, movement problems, feeding difficulties, and sometimes abnormalities in other organs such as the liver or heart. The severity varies widely depending on the specific genetic cause. Treatment is mainly supportive and focused on controlling seizures, supporting development through therapies, and managing other organ involvement. For a small number of specific CDG subtypes, targeted treatments such as dietary sugar supplementation (for example, mannose in PMM2-CDG or galactose in certain types) may help. However, for most forms, there is no cure, and management focuses on improving quality of life. A team of specialists including neurologists, metabolic geneticists, and therapists is usually needed to provide comprehensive care.
Also known as:
Key symptoms:
Seizures that are hard to controlDevelopmental delayIntellectual disabilityLow muscle tone (floppy baby)Difficulty feeding or swallowingPoor weight gain or failure to thriveAbnormal eye movementsMovement problems or unsteady walkingSpeech delayLiver problemsAbnormal fat distribution or unusual fat padsInverted nipplesCrossed eyes (strabismus)Small head size (microcephaly)Episodes of stroke-like symptoms
Variable
Can be inherited in different ways depending on the underlying gene
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Congenital disorder of glycosylation with epilepsy as a major feature.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Congenital disorder of glycosylation with epilepsy as a major feature at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Congenital disorder of glycosylation with epilepsy as a major feature.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Congenital disorder of glycosylation with epilepsy as a major feature.
Community
No community posts yet. Be the first to share your experience with Congenital disorder of glycosylation with epilepsy as a major feature.
Start the conversation →Latest news about Congenital disorder of glycosylation with epilepsy as a major feature
No recent news articles for Congenital disorder of glycosylation with epilepsy as a major feature.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific type of CDG does my child have, and what gene is affected?,Are there any targeted treatments or dietary supplements that could help my child's specific subtype?,What is the best seizure management plan, and when should I use rescue medication?,What developmental therapies should we start, and how often?,Are there clinical trials or research studies my child might be eligible for?,What other organs should be monitored, and how often do we need follow-up testing?,What does this diagnosis mean for future pregnancies and other family members?
Common questions about Congenital disorder of glycosylation with epilepsy as a major feature
What is Congenital disorder of glycosylation with epilepsy as a major feature?
Congenital disorders of glycosylation (CDG) with epilepsy as a major feature are a group of rare inherited metabolic conditions where the body cannot properly attach sugar molecules (glycans) to proteins and fats. This process, called glycosylation, is essential for many body functions, including brain development and nervous system signaling. When glycosylation goes wrong, it can affect many organs, but in this particular group, seizures (epilepsy) are one of the most prominent and troublesome symptoms. Children with these conditions typically develop seizures early in life, often in infancy
At what age does Congenital disorder of glycosylation with epilepsy as a major feature typically begin?
Typical onset of Congenital disorder of glycosylation with epilepsy as a major feature is infantile. Age of onset can vary across affected individuals.